176 related articles for article (PubMed ID: 25854351)
1. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
[TBL] [Abstract][Full Text] [Related]
2. Association of Mouse Double Minute 2 -309T>G Polymorphism with Acute Myeloid Leukemia in an Iranian Population: A Case- Control Study.
Soleymannejad M; Sheikhha MH; Neamatzadeh H
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3037-3041. PubMed ID: 31653152
[TBL] [Abstract][Full Text] [Related]
3. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
4. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
[TBL] [Abstract][Full Text] [Related]
5. Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: A case control study.
Maruei-Milan R; Heidari Z; Salimi S
J Cell Physiol; 2019 Aug; 234(8):12934-12940. PubMed ID: 30548972
[TBL] [Abstract][Full Text] [Related]
6. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
Xiong X; Wang M; Wang L; Liu J; Zhao X; Tian Z; Wang J
Leuk Res; 2009 Nov; 33(11):1454-8. PubMed ID: 19423162
[TBL] [Abstract][Full Text] [Related]
7. Influence of BCL2-938C>A and BAX-248G>A promoter polymorphisms in the development of AML: case-control study from South India.
Cingeetham A; Vuree S; Dunna NR; Gorre M; Nanchari SR; Edathara PM; Meka P; Annamaneni S; Digumarthi R; Sinha S; Satti V
Tumour Biol; 2015 Sep; 36(10):7967-76. PubMed ID: 25957891
[TBL] [Abstract][Full Text] [Related]
8. MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study.
El-Danasouri NM; Ragab SH; Rasheed MA; Ali El Saadany Z; Abd El-Fattah SN
Ann Clin Lab Sci; 2014; 44(4):449-54. PubMed ID: 25361931
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
10. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population.
Park SH; Choi JE; Kim EJ; Jang JS; Han HS; Lee WK; Kang YM; Park JY
Lung Cancer; 2006 Oct; 54(1):19-24. PubMed ID: 16876289
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
[TBL] [Abstract][Full Text] [Related]
12. [Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population].
Liu JN; Zhang XM; Guo YL; Sun T; Lin DX; Wen T
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):335-8. PubMed ID: 18953830
[TBL] [Abstract][Full Text] [Related]
13. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
14. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
15. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.
Asomaning K; Reid AE; Zhou W; Heist RS; Zhai R; Su L; Kwak EL; Blaszkowsky L; Zhu AX; Ryan DP; Christiani DC; Liu G
Clin Cancer Res; 2008 Jun; 14(12):4010-5. PubMed ID: 18559624
[TBL] [Abstract][Full Text] [Related]
16. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
Liu YC; Hsiao HH; Yang WC; Liu TC; Chang CS; Yang MY; Lin PM; Hsu JF; Lee CP; Lin SF
Mol Carcinog; 2014 Dec; 53(12):951-9. PubMed ID: 23818300
[TBL] [Abstract][Full Text] [Related]
17. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract][Full Text] [Related]
18. Murine double minute clone 2,309T/G and 285G/C promoter single nucleotide polymorphism as a risk factor for breast cancer: a Polish experience.
Piotrowski P; Lianeri M; Rubis B; Knuła H; Rybczyńska M; Grodecka-Gazdecka S; Jagodziński PP
Int J Biol Markers; 2012 Jul; 27(2):e105-10. PubMed ID: 22467100
[TBL] [Abstract][Full Text] [Related]
19. A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population.
Alshatwi AA; Hasan TN; Shafi G; Alsaif MA; Al-Hazzani AA; Alsaif AA
Fundam Clin Pharmacol; 2012 Jun; 26(3):438-43. PubMed ID: 21477265
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]